BRAF and non-small cell lung carcinoma: However, MNALCI showed no significant difference between EGFR mutant patients and wildtype patients in NSCLC, KRAS mutant and wildtype patients in CRC and BRAF mutant patients and wildtype patients in PTC (p = 0.680, 0.198 and 0.103, respectively).